Short Summary
The plaintiffs (Boehringer Ingelheim) sought confirmation of an interim injunction restraining the defendants (Msn Laboratories) from infringing their patent (IN 268846) related to Empagliflozin. The court addressed two main issues: the merits of the injunction and whether the defendant could challenge it without a written statement, ultimately allowing the defendant's application for vacation.
Detailed Summary
In the high-stakes world of pharmaceutical patents, speed often decides who wins the market. But rushing into court with an emergency injunction can backfire spectacularly if the other side knows the procedural playbook. The clash between Boehringer Ingelheim and MSN Laboratories over the diabetes drug Empagliflozin is a masterclass in why understanding procedural rights is just as critical as understanding the science.
Boehringer Ingelheim, the patent holder of Indian Patent No. 268846 covering Empagliflozin—a groundbreaking compound used in diabetes treatment—sought to protect its intellectual property from alleged infringement. Believing the threat was urgent, Boehringer moved swiftly and obtained an ex parte ad-interim injunction restraining MSN Laboratories from manufacturing or selling the allegedly infringing product. The order was passed without hearing the other side, a powerful but temporary legal weapon. MSN Laboratories, suddenly barred from operating under the shadow of this order, had to decide how to fight back.
Boehringer Ingelheim argued that the injunction was necessary to prevent irreparable harm to its patent rights and that the urgency justified the ex parte route. On the other side, MSN Laboratories challenged not just the substance of the injunction but the very procedure being used against it. The central legal friction was procedural: could MSN Laboratories seek vacation of the ex parte ad-interim order under Order XXXIX, Rule 4 of the Code of Civil Procedure (CPC) without first filing a formal written statement? Boehringer's position implicitly suggested that the defendant had to enter the formal pleadings before challenging the order. MSN Laboratories countered that a party dragged into court by an emergency order cannot be forced to submit a written statement as a precondition to defending itself.
The court sided with MSN Laboratories. It held that a defendant who has been hit with an ex parte ad-interim order has an independent right to apply for its vacation under Order XXXIX, Rule 4 CPC, and this right does not depend on whether a written statement has been filed. The court allowed MSN Laboratories' application, effectively vacating the injunction that Boehringer had secured in its rush to the courtroom. The ruling reaffirmed a critical procedural safeguard: emergency orders, no matter how powerful, are not immune from immediate challenge.
For founders and IP professionals, the lesson is clear: an ex parte injunction is a starting gun, not a finish line. If you are a patent holder, do not assume that securing an emergency order ends the dispute—be prepared for the defendant to challenge it immediately, and build your evidentiary record accordingly. If you are a defendant on the receiving end of such an order, remember that you have procedural weapons at your disposal even before you file a written statement. Knowing the rules of engagement under Order XXXIX, Rule 4 CPC can be the difference between being locked out of the market and reclaiming your freedom to operate.
Practitioner Note
This case demonstrates the evidentiary and procedural standards applied in patent matters before Himachal Pradesh High Court. Understanding the court's reasoning in Boehringer Ingelheim International GmbH vs Msn Laboratories Private Limited is valuable context for structuring arguments or assessing risk in similar proceedings.
Related Cases
The North Face Apparel CorpvsController of Patents and Designs
The North Face Apparel Corp challenged the Controller of Patents' refusal of its patent application (No. 202147026139) titled 'Systems and Methods for End-to-End Article Management' before the Madras High Court under Section 117A of the Patents Act, 1970. The Controller had rejected the application citing lack of inventive step over prior art documents D21-D24. The Court held that the Controller erred by dissecting the claims into isolated elements rather than assessing the invention as a whole, and overlooked the use of spectrophotometer and invisible markers for tracking the manufacturing process, which were not disclosed in the cited prior art. The appeal was allowed and the Controller was directed to grant the patent.
Aventose Energy Private LimitedvsThe Assistant Controller of Patents & Designs, Patent Office Chennai
Aventose Energy Private Limited appealed under Section 117A of the Patents Act, 1970 against the refusal of its patent application (No. 202141019671) for a 'System and Method for Operating Automobiles with an Electric Drivetrain' featuring safe mode activation upon fault detection. The Madras High Court found that the Assistant Controller had contradicted the First Examination Report (which accepted novelty) by subsequently holding the invention lacked novelty without giving the applicant an opportunity to be heard. The court further held that the Controller improperly conflated novelty with inventive step under Section 2(1)(ja) and failed to properly analyze the claims against prior art documents D1–D4.
Apex Laboratories Pvt LtdvsElder Lifescience and Ambico Ayurvedic Health Care
Apex Laboratories Pvt Ltd, the prior adopter and registered proprietor of the trademark ZINCOVIT (TM No. 487453 in Class 5) since 1988, sought interim injunction against Elder Lifescience and Ambico Ayurvedic Health Care for using the deceptively similar mark NEO ZINCOVIT. The applicant also claimed copyright infringement of its registered artistic works (A-108878/2014) covering colour scheme, get-up, and layout. The Madras High Court was satisfied that the respondents were attempting to piggyback on the applicant's goodwill and granted interim injunctions on all three applications covering trademark infringement, copyright infringement, and passing off.
Radico Khaitan LimitedvsPicadilly Agro Industries Limited
This Special Leave Petition arose from a judgment dated 29-05-2026 in CS No. 8/2025 passed by the District Judge, Karnal, Haryana, concerning a trademark dispute over the marks 'Cashmere' and 'Kashmyr' used in relation to beer and vodka. The Supreme Court noted that a First Appeal (FAO-COM-11-2026) was already pending before the Division Bench of the Punjab and Haryana High Court, listed for 28.10.2026. The Court disposed of the SLP without adjudicating it on merits, requesting the High Court to pass an appropriate order regarding the ad interim injunction on the scheduled date.
Maharaja Agrasen Technical Educational Society (Regd.)vsMaharaja Agrasen Himalayan Garhwal University
The plaintiff, Maharaja Agrasen Technical Educational Society, filed a suit for permanent injunction against the defendant, Maharaja Agrasen Himalayan Garhwal University, alleging infringement and passing off regarding the use of the words 'Maharaja Agrasen' in the defendant's name. The Delhi High Court had previously granted a restraint order on 10.07.2026. During the pendency of the suit, the parties arrived at a settlement dated 14.09.2026, under which the defendant agreed to change its name through a statutory amendment while being permitted limited transitional use of its existing name. The court recorded the settlement, modified the interim order accordingly, and listed the matter for compliance reporting on 13.07.2027.
Varahi Diamonds And Finance LimitedvsSahil Vinay Mehra Trading As Mehra Sons Jewellers & Anr.
This is a commercial suit filed by Varahi Diamonds And Finance Limited against Sahil Vinay Mehra Trading As Mehra Sons Jewellers & Anr. before the Delhi High Court. The order is primarily procedural, dealing with the registration of the plaint, issuance of summons, directions for filing pleadings, and an interim injunction application. The matter was referred to mediation, with parties directed to appear before the Delhi High Court Mediation and Conciliation Centre.
Dealing with a patent challenge?
Whether it's a Section 3(d) rejection, a post-grant opposition, or a FRAND dispute, Arctic's patent litigation team has handled it. Get a strategy call.
Disclaimer: This page contains an automated summary based on publicly available judicial records. The content is generated for informational purposes only and does not constitute legal advice. Always verify details against the original source judgment before relying on this information for any legal purpose. If you believe any information is inaccurate, please contact us.